L 759633: structure in first source [MeSH]
6h-dibenzo[b,d]pyran, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-methoxy-6,6,9-trimethyl-, (6ar,10ar)- : no description available [CHeBI]
| ID Source | ID |
|---|---|
| PubMed CID | 5311215 |
| CHEMBL ID | 57367 |
| SCHEMBL ID | 3700199 |
| CHEBI ID | 191050 |
| MeSH ID | M0304687 |
| Synonym |
|---|
| gtpl748 |
| l759633 |
| NCGC00161409-01 , |
| CHEMBL57367 , |
| l-759633 |
| (6ar,10ar)-1-methoxy-6,6,9-trimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene |
| CHEBI:191050 |
| 6h-dibenzo[b,d]pyran, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-methoxy-6,6,9-trimethyl-, (6ar,10ar)- |
| bdbm50287939 |
| (6ar,10ar)-3-(1,1-dimethyl-heptyl)-1-methoxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6h-benzo[c]chromene |
| l-759,633 |
| 174627-50-0 |
| SCHEMBL3700199 |
| AKOS024457097 |
| (6ar,10ar)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-methoxy-6,6,9-trimethyl-6h-dibenzo[b,d]pyran |
| HMS3650M20 |
| sr-01000946309 |
| SR-01000946309-1 |
| Q6456083 |
| l 759633 |
| l 759,633 |
| nsc792740 |
| nsc-792740 |
| Class | Description |
|---|---|
| 1-benzopyran |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 89.1251 | AID1490 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Cannabinoid receptor 1 | Homo sapiens (human) | Ki | 8.4465 | AID1127482; AID569312 |
| Cannabinoid receptor 2 | Homo sapiens (human) | Ki | 0.0132 | AID1127483; AID569313 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 ISSN: 2211-1247 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID569314 | Selectivity ratio of Ki for human CB1 to Ki for human CB2 | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 ISSN: 1768-3254 | Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2. |
| AID569312 | Displacement of [3H]CP 55940 from human CB1 receptor in cell free system | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 ISSN: 1768-3254 | Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2. |
| AID1127483 | Binding affinity to human CB2 receptor | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 ISSN: 1520-4804 | Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. |
| AID1127482 | Binding affinity to human CB1 receptor | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 ISSN: 1520-4804 | Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. |
| AID1127484 | Selectivity ratio of Ki for human CB1 receptor to Ki for human CB2 receptor | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 ISSN: 1520-4804 | Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. |
| AID569313 | Displacement of [3H]CP 55940 from human CB2 receptor in cell free system | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 ISSN: 1768-3254 | Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2. |
| AID1346728 | Human CB2 receptor (Cannabinoid receptors) | 1999 | British journal of pharmacology, Feb, Volume: 126, Issue:3 ISSN: 0007-1188 | Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cyclohexanol | cyclohexanols; secondary alcohol | solvent | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | |
| colforsin | acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol | adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | |
| sr 144528 | bridged compound; monochlorobenzenes; pyrazoles; secondary carboxamide | CB2 receptor antagonist; EC 2.3.1.26 (sterol O-acyltransferase) inhibitor | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | |
| am 630 | N-acylindole | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | ||
| 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol | alkylbenzene; ring assembly | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | ||
| guanosine 5'-o-(3-thiotriphosphate) | nucleoside triphosphate analogue | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congenital Zika Syndrome | 0 | 2020 | 2020 | 4.0 | high | 0 | 0 | 0 | 0 | 1 | 0 | |
| Disease Models, Animal | 0 | 2020 | 2020 | 4.0 | high | 0 | 0 | 0 | 0 | 1 | 0 | |
| Zika Virus Infection | 0 | 2020 | 2020 | 4.0 | high | 0 | 0 | 0 | 0 | 1 | 0 |